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Abstract
Background—Oxidative stress causes damage to many components of human cells (i.e.,
proteins, lipids, and DNA) and is involved in carcinogenesis. Nutrients with antioxidant properties
may protect against oxidative stress. We examined intake of antioxidants from diet and
supplements in relation to pancreatic cancer risk among participants of the VITamins And
Lifestyle (VITAL) Study.
Methods—Participants were 77,446 men and women, ages 50–76 years, who were residents of
western Washington State and completed a baseline questionnaire between 2000 and 2002.
Participants reported usual diet over the past year and use of supplements over the past 10 years,
in addition to demographic and lifestyle factors. During a median follow-up of 7.1 years, 184
participants developed pancreatic adenocarcinoma. Cox regression models were used to estimate
multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI) for seven
antioxidants: β-carotene, lutein and zeaxanthin, lycopene, vitamin C, vitamin E, selenium and
zinc.
Results—We observed an inverse association between dietary selenium and pancreatic cancer
risk (medium vs. low intake: HR 0.58, 95% CI 0.35–0.94; high vs. low intake: HR 0.44, 95% CI
0.23–0.85; p-trend = 0.01); however, when supplemental and dietary exposures were combined,
the association was no longer statistically significant.
Conclusions—Dietary selenium intake is inversely associated with risk of pancreatic cancer and
the observed association is attenuated by selenium supplementation.
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INTRODUCTION
Despite discouraging results from randomized trials 1–3, there remains an interest in anti-
oxidant nutrients and cancer risk. Antioxidants have been found to reduce oxidative DNA
damage and genetic mutations 4–6 and may protect against pancreatic carcinogenesis.
Epidemiological data have shown inconsistent results regarding the relation between
antioxidant intake and pancreatic cancer risk. Most case-control studies 7–15 have observed
an inverse association between dietary intake of vitamin C, vitamin E or β-carotene;
whereas other case-control studies 16–19 and all prospective studies 20–22 have shown null
results. One cohort study 20 and two meta-analysis of clinical trials 23, 24 have examined
antioxidant supplementation and pancreatic cancer, and all of them found null associations.
We examined pancreatic cancer risk associated with intake of seven antioxidant nutrients,
including β carotene, lutein and zeaxanthin, lycopene, vitamin C, vitamin E, selenium and
zinc from dietary and supplemental sources in a large population-based prospective study,
the VITamins And Lifestyle (VITAL) cohort. We hypothesized that intake of antioxidants
would be inversely related to incidence of pancreatic cancer.
MATERIALS AND METHODS
Study population
Participants were members of the VITAL cohort, a population-based prospective study
designed specifically to investigate the association between vitamin, mineral, and other
dietary supplements and cancer risk. Details of the study design, recruitment and study
implementation have been reported previously 25. Briefly, men and women ages 50–76
years at baseline, who lived in the 13-county region in western Washington State covered by
the Surveillance, Epidemiology, and End Results (SEER) cancer registry, were eligible to
participate. Between October 2000 and December 2002, baseline questionnaires, followed
by postcard reminders two weeks later, were mailed to 364,418 individuals based on a
commercial mailing list. Among these, 77,719 (21.3%) were returned and deemed eligible.
The study was approved by the Institutional Review Boards of the University of North
Carolina at Chapel Hill and the Fred Hutchinson Cancer Research Center (Seattle, WA).
Exposure assessment
Diet—Diet was assessed by a semi-quantitative food frequency questionnaire that captured
the consumption frequency and portion size of 120 foods and beverage items over the last
year and included adjustment questions on types of foods and preparation techniques 25.
Average dietary nutrient intake per day was estimated by the food frequency questionnaire
analytic program based on nutrient values from the Minnesota Nutrient Data System 26.
Supplement use—Respondents were queried about multivitamin use and their intakes of
16 vitamins and minerals from all other mixtures and single supplements during the 10-year
period prior to baseline, including duration in years, frequency in days/week and dose. 10-
year average supplemental nutrient intake per day was computed as (dose per day) × (days
per week/7) × (years/10), summed over individual supplements and micronutrient dose in
participant-reported multivitamins. The VITAL supplement questionnaire showed excellent
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reliability in a 3-month test-retest reliability sub-study of 220 randomly selected participants
with intraclass-correlation coefficients ranging from 0.69 to 0.87 27.
Total nutrition intake—Total nutrient intake per day was calculated by combining data
on the supplement use and dietary intake. Conversion factors were used for β-carotene 28
and vitamin E 29 to account for different chemical forms or differences in absorption. The
total nutrient intake was not calculated for lutein+zeaxanthin and lycopene because
supplement use information was available only in pills/day while the dietary intake was in
mcg/day.
Covariates—As part of the baseline questionnaire, participants also reported on personal
characteristics including age, gender, ethnicity, education, height, weight, recreational
physical activity, cigarette smoking, alcohol consumption, family history of cancer, and
medical history. From data on height and weight, we calculated body mass index (BMI; kg/
m2). Average total metabolic equivalent (MET) hours per week over the past 10 years were
calculated using the years, frequency, and published energy expenditure for different
activities. Cigarette smoking status was categorized as never, former (quit>10 years), recent
(quit<=10 years) and current.
Case ascertainment and follow-up
Cohort members were followed for incidence of pancreatic cancer from enrollment to
December 31, 2008; the median follow-up time was 7.1 years. Incident pancreatic cancer
was ascertained by linking the study cohort to the western Washington SEER cancer
registry. All incident cancer cases except non-melanoma skin cancer diagnosed within the
13-county area of western Washington State are reported to SEER. We ascertained 195
incident pancreatic cancer cases including 184 adenocarcinoma (ICD-O-3 code C250–C259,
C25.0–C25.3 or C25.7–C25.9) and 11 neuroendocrine tumors (C25.4). The remaining
participants were right-censored from the analysis at the earliest date of the following
events: withdrawal (22), emigration out of SEER catchment area (4,216), death (5,234) or
31 December 2008 (67,790).
Exclusions
For the present study, participants were excluded if they reported a positive (n=49) or
missing (n=213) history of pancreatic cancer at baseline. Eleven neuroendocrine tumors
were also excluded, leaving 77,446 participants in the study. In addition, participants were
excluded from the dietary analysis if they did not complete all pages of the food frequency
section (at least five items per page), if their energy intake was below 800 kcal for men or
600 kcal for women, or if their energy intake was above 5000 kcal for men and above 4000
kcal for women (n=7132), leaving 70,332 participants in the dietary analysis. Participants
were excluded from the supplement analysis if they did not provide usage information of
that supplement. Participants were excluded from the analysis of combining dietary intake
and supplement use if either was missing.
Statistical analysis
Cox proportional hazards models were used to estimate crude and adjusted hazard ratios
(HR) and 95% confidence intervals (CI) associated with antioxidant intake. For dietary
intake and total intake, the exposure was categorized as tertiles. For supplement use, the
intake levels were categorized as none, low (below median among users) and high (above
median among users). P-values for trend (P-trend) were calculated by using the continuous
variables with excluding values above 98th percentile for each exposure.
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We selected a priori potential confounders for the adjusted models: age (continuous),
gender, ethnicity (white, non-white), education (<=high school graduate, some college,
college or advanced degree), total energy intake (tertiles), BMI (<25, 25–30, >=30 kg/m2),
recreational physical activity (tertiles of MET for all recreational activities), cigarette
smoking status (never, former, recent, current), total alcohol consumption (tertiles of
average daily alcohol intake), family history of pancreatic cancer (yes/no) and use of
medication for diabetes (yes/no). Adding history of pancreatitis and pack-years of smoking
in the models did not change results materially thus they were not included in the final
models. Total energy intake was dropped from the supplement-use models because it did not
change the estimates. Missing values for covariates (9% with one or more covariates
missing) were imputed by chained equations in IVEware 0.2 (2012 University of Michigan).
All statistical analyses were performed using SAS, version 9.2 (SAS Institute Inc., Cary,
NC).
RESULTS
The cohort of participants included in this analysis was 52% female and 93% white. The
average age of the participants was 62 years at baseline (Table 1).
Table 2 shows the associations between average dietary antioxidant consumption and
pancreatic cancer risk. After adjustment for all a priori confounders, we observed a
statistically significant inverse association between dietary selenium intake and risk of
pancreatic cancer (HR (95% CI) for medium vs. low intake: 0.58 (0.35–0.94), high vs. low
intake: 0.44 (0.23–0.85), p-trend = 0.01). The crude HR and adjusted HR are very close
except for lycopene, vitamin C and selenium. Stepwise examination found that the
difference for lycopene was mainly due to adjustment for age (age was negatively correlated
with dietary lycopene intake, r = −0.05, p<0.0001), the difference for vitamin C was mainly
due to adjustment for smoking [current smokers and recent quitters had a significantly lower
intake of vitamin C (mean 104.3 mg/day) than never smokers (mean 125.5 mg/day) and
long-term quitters (mean 125.5 mg/day) (ANOVA p-value <0.0001)], and the difference for
the trace element selenium was mainly due to adjustment for total energy intake (total
energy intake was highly correlated with dietary selenium intake, r = 0.88, p-value<0.0001).
Table 3 shows associations between 10-year antioxidant exposure from supplement sources
and pancreatic cancer risk. In this study, most of the supplemental nutrient intake was from
multivitamins except for vitamin C and vitamin E; therefore, supplement use results for
vitamin C, vitamin E and multivitamins are presented in the Table. We observed no
associations between use of any individual supplement or multivitamin supplements and
pancreatic cancer. For supplemental selenium (mainly from multivitamins), the adjusted
HRs (95% CI) were: 0.99 (0.70–1.41) for low intake (<20 mcg/day) and 0.73 (0.51–1.06)
for high intake (≥20 mcg/day) vs. non-user, and the P-trend was 0.60.
When dietary and supplement uses of antioxidants were combined (Table 4), a significant
inverse association was seen among those who consumed a medium level of selenium (HR:
0.59; 95% CI: 0.37–0.93), but not among those in the highest tertile of selenium intake (HR:
0.69; 95%CI: 0.39–1.20) (Table 4). Trend test were suggestive of a possible inverse
association between total β-carotene intake and pancreatic cancer risk (P-trend=0.03), but
the HR did not reach statistical significance for either medium or high level of intake.
DISCUSSION
In this cohort study, we investigated the intake of seven antioxidants from dietary and
supplement sources in relation to pancreatic cancer risk. Our results provided evidence that
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dietary selenium intake is inversely associated with risk of pancreatic cancer. We did not
observe strong evidence with intake of other antioxidants.
Epidemiological studies have indicated an inverse relation between selenium intake and the
incidence of certain cancers, such as colorectal cancer 30, bladder cancer 31, lung cancer 32,
and prostate cancer 33, although the results were not all consistent 34. A cancer prevention
trial in Finland 22 assessed baseline dietary selenium intake with a dietary history
questionnaire and found no association with pancreatic cancer risk. A recent study with the
European Prospective Investigation of Cancer (EPIC) cohort in UK where dietary selenium
was assessed using 7-day food diaries at baseline found that high intake of selenium was
associated with a reduced risk of pancreatic cancer 35. Moreover, two studies have identified
an inverse association between biomarkers of selenium and pancreatic cancer risk, including
a small nested case-control study with 22 cases and 44 controls using serum 36 and a recent
case-control study with 118 cases and 399 controls using toenails 37. In line with these
biomarker studies, our study found that selenium intake from diet was inversely associated
with pancreatic cancer, even after adjustment for a number of potential confounding
variables. We also found that selenium supplementation does not appear to provide
additional benefit beyond the effect observed for dietary intake of selenium alone, as the
analysis of selenium supplement use (intake mostly from multivitamin supplements) showed
null results and the association between selenium intake and pancreatic cancer was
substantially attenuated and became statistically non-significant when supplemental
selenium was added to dietary selenium as the exposure.
Selenium is a trace element essential to human health. It plays an important role in thyroid
hormone metabolism, antioxidant defense systems and immune function 38. Selenium has
several anti-carcinogenic mechanisms including inactivating oxygen free radicals, initiating
DNA repair, and inducing apoptosis 39. However, animal and in-vitro studies have also
shown that selenium promotes malignant cell transformation and protects tumor cells from
stress-induced apoptosis 40. Furthermore, a randomized trial of supplemental selenium found
that selenium supplementation was linked to increased risk of type 2 diabetes mellitus 41, a
risk factor for pancreatic cancer. Our results suggest that there might be an optimal range of
selenium level that maximizes its anti-carcinogenicity or reduce the carcinogenicity. Further
investigation is necessary to confirm this finding and determine the optimal dose. A study in
British adults observed that higher selenium status was associated with adverse blood lipid
profile 42, and another study among U.S. adults found that increasing serum selenium levels
were associated with decreased mortality up to 130 ng/ml and raised the concern that higher
serum selenium levels beyond that might be associated with increased mortality 43. Along
with the previous studies, our study suggests that selenium supplementation may not be
beneficial, especially for people already with a high selenium status.
Four other prospective studies have investigated dietary intake of other antioxidants (vitamin
C, vitamin E, β-carotene, lycopene) in relation to pancreatic cancer, and all of them
observed null or weak findings 20–22, 35. Our study also observed null findings for these
antioxidants, with one exception: we observed a decreased risk with the highest intake of β-
carotene. The discrepancy with previous studies could be due to different populations or our
finding could be due to chance.
This study has several strengths. The VITAL cohort is a prospective study designed
specifically to investigate supplement use with cancer risk. Supplement users were targeted
at recruitment to increase power as the recruitment letter described the study as one on
supplement use and cancer risk, but the study was not restricted to supplement users.
Information on supplementation was collected for the 10 years prior to base-line, providing
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long-term intake. We collected extensive information on cancer risk factors, and we were
able to carefully control for the potential confounding effects.
This study also has several limitations. Although our detailed supplement assessment
yielded very good validity and reliability results 27, recall error from the self-reported food
frequency questionnaire and supplement use was inevitable. Moreover, dietary selenium in
food varies depending on where the food is grown (e.g. the selenium level in soil varies
from 0.10 ppm to 1.31 ppm among counties in Washington 44) and this information was not
included in the determination of the selenium content of foods, so these non-differential
measurement errors could have led to some attenuation of the results. Another limitation is
that we examined a relatively large number of dietary exposures in this work, increasing the
probability of a spurious result. Lastly, although we adjusted for education level and race in
our final model, there may still be residual confounding from social-economic status.
However, we do not think this a big concern because the current literature reveals only a
weak or null association of social-economic status and pancreatic cancer risk 45–48. In our
analysis, further adjustment for household income did not change the conclusions.
In summary, our study did not observed an association between the use of antioxidant
supplements and pancreatic cancer incidence. Our data suggest that dietary selenium is
associated with reduced risk of pancreatic cancer, but the findings need replication in other
populations.
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Table 1
Selected demographic characteristics, VITAL cohort, 2000–2008
Mean Std
Age (years) 61.99 7.45
BMI (kg/m2) 27.41 5.17
Physical activity (MET, hr/wk) 10.88 13.89
Alcohol (g/d) 8.17 15.45
Total energy intake (kcal/day) 1855.12 773.95
Frequency* %
Sex
    Female 40225 51.94
    Male 37221 48.06
Race
    White 72220 93.25
    Others 5226 6.75
Education
    ≤High school graduate 15377 20.2
    Some college 29161 38.31
    College or advanced degree 31587 41.49
Smoking status
    No 36459 47.46
    Long-term quitters (>10 years) 28148 36.64
    Current and short-term quitters (<=10 years) 12216 15.9
Family history of pancreatic cancer
    Yes 2834 3.71
    No 73640 96.29
History of pancreatitis
    Yes 650 0.84
    No 76777 99.16
History of Diabetes
    Yes 5411 6.99
    No 72034 93.01
Abbreviations: BMI (body mass index), MET (Metabolic equivalent for all activities).
*
Totals were not all equal to 77446 due to missing values.


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cancer. Author manuscript; available in PMC 2014 April 01.
